Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.
about
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor MicroenvironmentTherapeutic Lymphoid Organogenesis in the Tumor MicroenvironmentInnate and adaptive immune cells in the tumor microenvironmentTargeting and utilizing primary tumors as live vaccines: changing strategiesCancer immunotherapyFacilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 BlockadeThe efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunityChemokine expression in melanoma metastases associated with CD8+ T-cell recruitmentLIGHT induces distinct signals to clear an AAV-expressed persistent antigen in the mouse liver and to induce liver inflammation.Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regressionThe therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunityLigand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunityLIGHT/TNFSR14 can regulate hepatic lipase expression by hepatocytes independent of T cells and Kupffer cells.Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapyImmunoregulation by tumor necrosis factor superfamily member LIGHTHigh endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytesMyocyte-derived Tnfsf14 is a survival factor necessary for myoblast differentiation and skeletal muscle regenerationAdaptive Immune Responses and HER2/neu Positive Breast Cancer.Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression.Ectopic lymphoid tissues and local immunity.Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory.Targeting tumors with LIGHT to generate metastasis-clearing immunityTherapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatmentCostimulatory and coinhibitory receptors in anti-tumor immunityImmune oppression array elucidating immune escape and survival mechanisms in uveal melanoma.Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effectPiperine suppresses tumor growth and metastasis in vitro and in vivo in a 4T1 murine breast cancer model.Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.Targeting costimulatory molecules to improve antitumor immunity.Immunotherapy and tumor microenvironmentAndrogen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse.Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.
P2860
Q26796305-ABF419F0-0645-42A1-8C4A-34088B3034B0Q26799123-F526AA97-B13D-494C-8FB0-7002B7CD9AC5Q27008342-57369A4D-3FBF-4BA0-B421-1D6F8EBC9EE5Q27009348-3F162D0A-35E4-4CFA-BAB9-6D2DCBF88905Q27026870-6CC1AAEB-4364-4FAF-A67D-652C9E3013ECQ28119095-FF998508-3B68-4EEB-B780-164C4A0D6758Q28304923-9E03A79D-B958-4E55-8C6A-D622DB29FE17Q30415355-C52CD5ED-DDD2-44FE-821D-499B6AF886F0Q33586211-FE752983-9620-466B-A245-FCF5EE4800B1Q33862487-83FD3745-F17B-429E-8C7D-6DA01DBBE1D1Q34073138-F074D9BE-BF72-4F99-B2BA-4CD2A76C0189Q34153811-9D20DCB0-4660-4C20-8D5B-062A762F693DQ34565128-718337CD-B422-4603-8460-FA505E558A4BQ35721553-D9C4E2D6-733E-40A6-A954-192393537042Q36253506-0E58E8A0-0C78-4944-96D4-830421754E92Q36373347-89E280A9-4EC1-4BF9-A8B1-4F740BF38E2FQ36485188-D12B3FE0-34B4-4E01-B37E-462672F92DF3Q36607857-290301F4-E4E6-431C-BF6B-4CB463701F73Q36984725-D690AB37-2DC9-4AE2-B912-835D2C14C8D1Q37075235-58185D03-1638-451B-A7C5-002C7E313F45Q37102329-21FA2CB1-4F17-46E2-A109-696EB6061748Q37175025-63EBC6DC-654B-4DD7-8A13-879ECCA83C09Q37268974-92FEE730-6EC8-42F7-B3C3-58A0AC49CC0EQ37474920-2C5DE7B8-29C8-435C-A1CD-F2356E6BA8ACQ37500476-A44DD292-31ED-4C31-A57A-EDF3A1E9007BQ37729679-3F91597A-63FA-4731-AA36-AB90C68FE3A6Q37729960-38A8E288-3F05-4718-9F67-B9CCE2158519Q37824051-66983F66-76E7-4D85-A4BE-295696FD2962Q38002404-DB3A850C-81CD-4F2D-AC90-76BAAAD1AAB6Q38610306-8629B65E-2D16-4519-AA10-35EC060F23D5Q38780080-DF76339B-A405-4B4E-A64D-75A95B5A552BQ39245218-EE2B13A0-AE70-49AE-BAAE-9F3489089DAFQ39934421-AF0F94E5-1C39-4BEB-B89B-2E72CA720CC0Q42391294-498FF9B0-9369-4ECF-B581-3422ACB08B8AQ47335259-B42391AC-63BC-4892-AEE4-842CDAD69362Q52720460-1AA89BAF-D484-4C8B-AA48-2566C1BDA366
P2860
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Targeting the primary tumor to ...... ion of spontaneous metastases.
@ast
Targeting the primary tumor to ...... ion of spontaneous metastases.
@en
type
label
Targeting the primary tumor to ...... ion of spontaneous metastases.
@ast
Targeting the primary tumor to ...... ion of spontaneous metastases.
@en
prefLabel
Targeting the primary tumor to ...... ion of spontaneous metastases.
@ast
Targeting the primary tumor to ...... ion of spontaneous metastases.
@en
P2093
P2860
P1476
Targeting the primary tumor to ...... ion of spontaneous metastases.
@en
P2093
Campbell Kaynor
Hans Schreiber
Sogyong Auh
Thomas F Gajewski
Xiaojuan Liu
Xinzhong Wang
Yang-Xin Fu
Youjin Lee
P2860
P304
P356
10.4049/JIMMUNOL.179.3.1960
P407
P577
2007-08-01T00:00:00Z